Parathyroid Hormone Global Market Report 2024

The parathyroid hormone market size has grown steadily in recent years. It will grow from $2.35 billion in 2023 to $2.43 billion in 2024 at a compound annual growth rate (CAGR) of 3.5%. The growth observed in the historical period can be attributed to several factors, including an increased prevalence of chronic kidney disease, a growing awareness of disorders related to parathyroid hormone, a rising demand for parathyroid hormone analogs, increased governmental funding allocated for parathyroid hormone research, and an overall rise in disposable incomes.

The parathyroid hormone market size is expected to see steadily grown in the next few years. It will grow to $3.5 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. Anticipated growth in the forecast period can be linked to several key factors, including the expanding geriatric population, the growth of private healthcare sectors, the emergence of new indications, the advancement of precision medicine, a heightened awareness of bone health, and an increased accessibility to healthcare services. Major trends expected during this period encompass advancements in parathyroid hormone testing, innovations in drug delivery methods, the development of combination therapies, integration of digital health technologies, and a focus on sustainability and green initiatives within the industry.

The market for parathyroid hormones anticipates growth due to rising osteoporosis prevalence. In January 2021, Osteoporosis, characterized by reduced bone mass leading to higher fracture risks, affects approximately 1.4 million Canadians, primarily postmenopausal women and the elderly. Parathyroid hormones, regulating calcium levels, are administered via daily subcutaneous injections to mitigate fracture risks in osteoporosis patients. This surge in osteoporosis cases is expected to contribute to the expansion of the parathyroid hormone market.

The escalating incidence of hypocalcemia is projected to drive the parathyroid hormone market. Hypocalcemia, a condition marked by low blood calcium levels, is managed by parathyroid hormones, pivotal in calcium regulation. In April 2021, Reports indicate over 3.5 billion individuals at risk of calcium deficiency, spurring a market demand for treatments. As parathyroid hormones aid in managing hypocalcemia, their market growth is substantiated by this increasing incidence. Companies within the parathyroid hormone market prioritize biosimilar development. Biosimilars, akin to FDA-approved biologics, offer cost-effective treatment without compromising efficacy. Notably, Theramex introduced Livogiva in January 2021, a novel form of teriparatide for postmenopausal women at high osteoporosis risk. This emphasis on biosimilars signifies a strategic focus of parathyroid hormone manufacturers to broaden treatment accessibility while maintaining standards.

Key players in the parathyroid hormone market concentrate on innovative products like upasita IV Injection syringes to drive revenues. Specifically designed for intravenous delivery, these syringes serve to administer medications directly into the bloodstream. Sanwa Kagaku Kenkyusho Co. Ltd.'s upasita IV Injection syringes, launched in August 2021, target secondary hyperparathyroidism in dialysis patients by regulating excessive parathyroid hormone secretion. This innovation caters to enhanced treatment options within the market segment.

Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, announced its decision to acquire Shire Plc for $46 billion. The acquisition is expected to accelerate the delivery of medicines to patients around the world with an expanded scale and geographical footprint by Takeda Pharmaceutical Company. It also increases the levels of the parathyroid hormone, natpara. Shire Plc is a pharmaceutical company based in the United States that specializes in innovative and rare disease drugs.

Major companies operating in the parathyroid hormone market include Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Shire PLC, Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc., Gedeon Richter Plc., Abbott Laboratories, Amgen Inc., Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Bayer Healthcare, Becton Dickinson and Company, Ethicon Inc., Genentech Inc., Medtronic Inc., Mylan Laboratories, Novo Nordisk, Smith & Nephew PLC, Stryker Corporation, Zimmer Biomet Holdings Inc.

North America was the largest region in the parathyroid hormone market in 2023. The Middle East is expected to be the fastest-growing region in the global parathyroid hormone market share during the forecast period. The regions covered in the parathyroid hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the parathyroid hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Within the realm of parathyroid hormone products, there are recombinant parathyroid hormone and parathyroid hormone analogs. Recombinant parathyroid hormone, resembling natural parathyroid hormone, is utilized in treating osteoporosis. These products cater to conditions like hypocalcemia and hypoparathyroidism and are used across various healthcare settings such as hospitals, clinics, and others.

The parathyroid hormone market research report is one of a series of new reports provides parathyroid hormone market statistics, including parathyroid hormone industry global market size, regional shares, competitors with a parathyroid hormone market share, detailed parathyroid hormone market segments, market trends and opportunities, and any further data you may need to thrive in the parathyroid hormone industry. This parathyroid hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The parathyroid hormone market consists of sales of parathormone and calcitonin. Values in this market are ''factory gate values,'' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.